Advancing Immunotherapy & Prevention

1900 Lake Park Drive, Suite 380 ♦ Atlanta, GA 30080

Tel: (678) 384-7220, Fax: (678) 384-7281

www. geovax.com ♦ OTCQB: GOVX

Forward Looking Statements

Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

GeoVax…A Compelling Opportunity

- **Developing immunotherapies and infectious disease prevention based on**
  - Single-dose
  - Durable immunity
  - No adjuvant
  - Extensive safety profile
  - Cost-effective manufacturing
- **Leveraging internal and external expertise to minimize development risk**

GeoVax MVA-VLP Vaccine Technology

- **MVA Vector = Safety**
  - Replication-deficient in mammalian cells → Vaccination
  - Replication competent in avian cells → Manufacturing
- **Transgenes: Antigen = Immunogenicity**
- **Vector + Antigen = MVA-(VLP) Platform**





Advantages of MVA-VLP vaccines

- Inherently safe ✓
- Non-replicating in host ✓
- Potential for single dose protective immunity ✓
- Not hindered by pre-existing immunity to vector ✓
- Self-adjuvant ✓
- Thermostable > can be lyophilized ✓
- Established methods for manufacturing ✓

Advantages of GeoVax Technology

Technology	Single-Dose Immunity	Immunogenicity	Optimized VLP Formation	Transgene Stability
GeoVax MVA-VLP	Yes	Excellent	Yes	Excellent
Competitive MVA Technologies	No ✓	Limited ✓	No ✓	??Unknown?? ✓

Cost-Effective Manufacturing and No Adjuvant Necessary

Broadly Validated Technology

		Target Identification	Preclinical Validation	Clinical Trials	
				Phase 1	Phase 2
Immuno-Oncology					
Solid Tumors					
HPV-associated Head and Neck Cancer					
Infectious Disease					
HIV (HVTN)	*GOVX-B11*				
HIV (functional cure, AGT)	*GOVX-B01*				
Lassa Fever	*GEO-LM01*				
Ebola, Marburg, Sudan	*GEO-EM01*				
Zika Virus	*GEO-ZM02*				
Malaria					
Hepatitis B (chronic infection)					

Advancing Immunotherapy

1900 Lake Park Drive, Suite 380 ♦ Atlanta, GA 30080

Tel: (678) 384-7220, Fax: (678) 384-7281

www. geovax.com ♦ OTCQB: GOVX

GeoVax Cancer Immunotherapy Focus

GeoVax has developed a **combination cancer vaccine strategy**:

- GeoVax novel Cancer Immunotherapy uses combinations of:
  - MVA-VLP cancer vaccines
  - Select proteins, peptides (e.g., MUC1; Cyclin B1),
  - Immune check-point inhibitors (e.g., anti-PD1)

For treating and potentially preventing solid tumors.



GeoVax Concept to Cancer Immunotherapy

STIMULATE

MVA-VLP with TAA to provoke immune system
(POC completed)

BLOCK

checkpoint inhibitor to reverse immune tolerance
(POC completed)

KILL

achieve oncolysis using armed vaccinia virus

TUMOR



REGRESSION

GeoVax Cancer Vaccines

- **MUC1 – aberrantly glycosylated in many cancers**
  - In collaboration with ViaMune, University of North Carolina at Charlotte & University of Pittsburgh
- **CyclinB1 – overexpressed in certain cancers**
  - In collaboration with Vaxeal
- **HPV head and neck cancers**
  - Internal
  - E6/E7 antigens



MVA-VLP-MUC1

- **MUC1 engineered to be displayed on VLPs produced *in vivo***
- **5 repeats of the VNTR region of MUC1**
- **Overexpression of MUC1 by MVA leads to accumulation of hypoglycosylated protein**
- **Potentially useful against all MUC1+ cancers**
  - Pancreatic
  - Colorectal
  - Prostate
  - Lung
  - Breast
  - Others





Therapeutic Experiment Results



As in the initial experiment, MVA+MTI+CPI arrested tumor growth and shrank tumors

Prevention Experiment Results

- **MUC1 Tumor Associated Antigen (TAA):**
  - Combination therapy:
    - MVA-VLP-MUC1 and MUC1 peptide
  - **GeoVax MVA-VLP combination achieved tumor prevention**
- **Indications:**
  - Lung, colorectal, breast, gastric, prostate, colon, pancreas, etc.



GeoVax Cancer Immunotherapy Next Steps

- **Further validate GeoVax novel cancer vaccine approach using other target antigens & novel check-point inhibitors that can be expressed by the vector and not administered separately**
- **Complete POC related to using oncolytic virus to achieve tumor cell lysis (e.g. KILLing the tumor)**
- **Proceed to clinical trials and technology validation**

GeoVax Developments in Infectious Disease Vaccines

1900 Lake Park Drive, Suite 380 ♦ Atlanta, GA 30080

Tel: (678) 384-7220, Fax: (678) 384-7281

www. geovax.com ♦ OTCQB: GOVX

GeoVax HIV Preventive Vaccine
Advancing in Human Trials

- **Excellent safety and immunogenicity: Phase 1 & 2a human clinical trials**
- **Superior antibody profile and durability compared to Sanofi Thailand Phase 3 clinical trial (RV144)**
- **Preventive vaccine: HVTN 132 – Scheduled start H2 2019**
- **Therapeutic vaccine: Phase 1 trial to begin H2-2019**
  - Collaboration with American Gene Technologies for **"functional cure"** effort;

Focused on Areas of Critical Healthcare Need

Hemorrhagic Fever Vaccines

- Four vaccines covering all major hemorrhagic fevers:
  - **Ebola**
  - **Sudan**
  - **Marburg**
  - **Lassa**

Zika Vaccine (GOVX-ZM01)

- A novel vaccine candidate that removes risk of ADE

Malaria Program

- Vaccine antigens covering all 3 stages of malaria infection



Hemorrhagic Fever Vaccines-Unparalleled Success

EBOLA Monkey



MARV Guinea Pig



LASSA Normal mice



- **Ebola vaccine – 100% Protection, Single-Dose**
  - In 2 rodent models and Nonhuman Primates
  - Anticipating govt support (NIH, BARDA)
- **Marburg vaccine – 100% Protection,**
  - In Guinea Pig model
  - Anticipating govt support (NIH, BARDA)
- **Lassa vaccine – 100% Protection, Single-Dose**
  - In a lethal (intracerebral inoculation) mouse model
  - Ongoing Govt. Support
    - Fast-Track Phase I / II SBIR grant from NIH
    - CDMRP grant from DoD for production of Master Seed Virus
- **Sudan Vaccine, awaiting animal testing**

Potential to develop a single tetravalent vaccine → Significant commercial opportunity

Zika Vaccine Program – Progressing to Clinic

- **Novel vaccine design**
  - **Competitive Advantage**
    - No risk of Antibody Dependent Enhancement (ADE) of infection against Dengue or other flaviviruses
- **Excellent preclinical data**
  - Immunocompetent outbred mice vaccinated IM and challenged IC (very rigorous model)
  - **100% single-dose survival in vaccinated mice**
  - 90-100% death in saline controls within 1 week
  - Effective clearance - no virus recovered from brains of vaccinated and Zika-challenged mice
- **Completed Immunogenicity and Efficacy studies in Nonhuman Primates with NIH grant support**

(Nature's Scientific Reports 2017)



SBIR·STTR
America's Seed Fund

Strong IP Protection

- **Patent Portfolio**
  - Owner of Record Patents
    - U.S. – 11 applications pending
    - Non-U.S. – 17 application pending
  - Licensed Patents
    - U.S. – 10 issued, 2 applications pending
    - Non-U.S. – 14 issued, 2 applications pending

GeoVax Value → Proprietary Expertise in Vaccine Vector Development

GeoVax Scientific Advisors

Thomas Monath, MD (Chairman)

- Managing Director & CSO, Crozet BioPharma
- Acambis, Hookipa, PaxVax, NewLink Genetics, PerkinElmer

Olja Finn, PhD

- Prof. Immunology and Surgery, Univ. of Pittsburgh

Barney Graham, MD, PhD

- Sr. Investigator, VRC, NIAID/NIH

Stanley Plotkin, MD

- Vaxconsult, LLC
- Sanofi Pasteur

Scott Weaver, PhD

- Director UTMB Institute for Human Infections and Immunity

A Compelling Opportunity



- ✓ **Developing novel, patented vaccines and immunotherapies based on a unique technology & expertise**
  - ❖ **Robust, durable immunity, single-dose, no adjuvant, cost-effective manufacturing, safe vaccines**
- ✓ **Focused on critical major medical needs with differentiated advantages**
- ✓ **Translational programs underway to pursue clinical and regulatory development**

Advancing Immunotherapy & Prevention

1900 Lake Park Drive, Suite 380 ♦ Atlanta, GA 30080

Tel: (678) 384-7220, Fax: (678) 384-7281

www. geovax.com ♦ OTCQB: GOVX